OBJECTIVE: HIV-1 natural viral suppressors (NVSs) demonstrate an intrinsic ability to control HIV-1 replication in the absence of antiretroviral therapy. The objective of this study was to investigate whether HIV-infected NVSs also demonstrate enhanced ability to control hepatitis C virus (HCV) infection, and whether HCV infection in the NVSs affects the degree of HIV control. DESIGN AND METHODS: A cross-sectional study was undertaken to compare HCV-related parameters in the NVS to the two race-matched cohorts (HIV/HCV-coinfected or HCV-monoinfected patients). Within the NVS, HIV-related parameters were compared based on the presence or absence of chronic HCV. RESULTS: NVS patients had a significantly higher clearance rate of HCV at 23.3% (seven of 30), compared to the 6.5% (23 of 350) of HIV/HCV-coinfected and 9.1% (32 of 350) of HCV-monoinfected patients (P = 0.005 and P = 0.024, respectively). Apart from the HCV clearance rate, there was no significant difference in HCV-related parameters such as HCV viral load or liver histology in the NVS with chronic HCV compared to HCV/HIV-coinfected patients or HCV-monoinfected patients. However, NVS patients with chronic HCV infection had statistically significant lower CD4 cell count and CD4%, and lower CD4/CD8 ratio compared to those NVSs without chronic HCV infection (P = 0.029, P = 0.046, and P = 0.062, respectively). CONCLUSION: It appears that some NVS patients have the ability to effectively control multiple agents that can cause chronic viral infections. In addition, it appears that the presence of chronic HCV infection within the NVS adversely affects immunological parameters.
OBJECTIVE:HIV-1 natural viral suppressors (NVSs) demonstrate an intrinsic ability to control HIV-1 replication in the absence of antiretroviral therapy. The objective of this study was to investigate whether HIV-infected NVSs also demonstrate enhanced ability to control hepatitis C virus (HCV) infection, and whether HCV infection in the NVSs affects the degree of HIV control. DESIGN AND METHODS: A cross-sectional study was undertaken to compare HCV-related parameters in the NVS to the two race-matched cohorts (HIV/HCV-coinfected or HCV-monoinfected patients). Within the NVS, HIV-related parameters were compared based on the presence or absence of chronic HCV. RESULTS: NVS patients had a significantly higher clearance rate of HCV at 23.3% (seven of 30), compared to the 6.5% (23 of 350) of HIV/HCV-coinfected and 9.1% (32 of 350) of HCV-monoinfected patients (P = 0.005 and P = 0.024, respectively). Apart from the HCV clearance rate, there was no significant difference in HCV-related parameters such as HCV viral load or liver histology in the NVS with chronic HCV compared to HCV/HIV-coinfectedpatients or HCV-monoinfected patients. However, NVS patients with chronic HCV infection had statistically significant lower CD4 cell count and CD4%, and lower CD4/CD8 ratio compared to those NVSs without chronic HCV infection (P = 0.029, P = 0.046, and P = 0.062, respectively). CONCLUSION: It appears that some NVS patients have the ability to effectively control multiple agents that can cause chronic viral infections. In addition, it appears that the presence of chronic HCV infection within the NVS adversely affects immunological parameters.
Authors: Pedro Castro; Montserrat Laguno; Meritxell Nomdedeu; Anna López; Montserrat Plana; Emilio Fumero; Teresa Gallart; Josep Mallolas; José M Gatell; Felipe García Journal: AIDS Res Hum Retroviruses Date: 2007-07 Impact factor: 2.205
Authors: I Bakr; C Rekacewicz; M El Hosseiny; S Ismail; M El Daly; S El-Kafrawy; G Esmat; M A Hamid; M K Mohamed; A Fontanet Journal: Gut Date: 2006-01-24 Impact factor: 23.059
Authors: Justin R Bailey; Kara G Lassen; Hung-Chih Yang; Thomas C Quinn; Stuart C Ray; Joel N Blankson; Robert F Siliciano Journal: J Virol Date: 2006-05 Impact factor: 5.103
Authors: D L Thomas; J Astemborski; R M Rai; F A Anania; M Schaeffer; N Galai; K Nolt; K E Nelson; S A Strathdee; L Johnson; O Laeyendecker; J Boitnott; L E Wilson; D Vlahov Journal: JAMA Date: 2000-07-26 Impact factor: 56.272
Authors: Chia C Wang; Elizabeth Krantz; Jared Klarquist; Meighan Krows; Lanamarie McBride; Edward P Scott; Thomas Shaw-Stiffel; Scott J Weston; Hanne Thiede; Anna Wald; Hugo R Rosen Journal: J Infect Dis Date: 2007-10-31 Impact factor: 5.226
Authors: Jason Grebely; Jesse D Raffa; Calvin Lai; Mel Krajden; Brian Conway; Mark W Tyndall Journal: Can J Gastroenterol Date: 2007-07 Impact factor: 3.522
Authors: Laura Capa; Vincent Soriano; Javier García-Samaniego; Marina Nuñez; Miriam Romero; Almudena Cascajero; Fernando Muñoz; Juan González-Lahoz; José M Benito Journal: J Med Virol Date: 2007-05 Impact factor: 2.327
Authors: Maria Salgado; Gregory D Kirk; Andrea Cox; Alleluiah Rutebemberwa; Yvonne Higgins; Jacquie Astemborski; David L Thomas; Chloe L Thio; Mark S Sulkowski; Joel N Blankson Journal: AIDS Date: 2011-01-28 Impact factor: 4.177
Authors: Mohammad M Sajadi; Nahzinine Shakeri; Rohit Talwani; Charles D Howell; Ruth Pakyz; Robert R Redfield; Afshin Parsa Journal: Clin Transl Sci Date: 2011-08 Impact factor: 4.689
Authors: Ahmed A Quadeer; Raymond H Y Louie; Karthik Shekhar; Arup K Chakraborty; I-Ming Hsing; Matthew R McKay Journal: J Virol Date: 2014-04-23 Impact factor: 5.103
Authors: Benoît Vingert; Daniela Benati; Olivier Lambotte; Pierre de Truchis; Laurence Slama; Patricia Jeannin; Moran Galperin; Santiago Perez-Patrigeon; Faroudy Boufassa; William W Kwok; Fabrice Lemaître; Jean-François Delfraissy; Jacques Thèze; Lisa A Chakrabarti Journal: J Virol Date: 2012-07-25 Impact factor: 5.103
Authors: Alice K Asher; Glenn-Milo Santos; Jennifer Evans; Emily K Dokubo; Tzong-Hae Lee; Jeffrey N Martin; Steven G Deeks; Leslie H Tobler; Michael Busch; Peter W Hunt; Kimberly Page Journal: AIDS Date: 2013-11-13 Impact factor: 4.177
Authors: Peter W Hunt; Alan L Landay; Elizabeth Sinclair; Jeffrey A Martinson; Hiroyu Hatano; Brinda Emu; Philip J Norris; Michael P Busch; Jeffrey N Martin; Cicely Brooks; Joseph M McCune; Steven G Deeks Journal: PLoS One Date: 2011-01-31 Impact factor: 3.240